<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=213807269037206&ev=PageView&noscript=1">
Blog

Compliance In Focus

remote services

LEARN MORE ABOUT REMOTE SERVICES

Keep Your Clinical Trial Moving from a Distance

You want to keep your trial on track, but physical distancing and travel restrictions have made it difficult. Fortunately, IMARC has experience providing remote services.

FILTER BY:

Newest Post

Posted by Rachel Martukovich on Wed, Aug 05, 2020

Transforming the 510(k) Program

Recently the FDA released an announcement outlining plans to further modernize the 510(k) clearance pathway. This briefing falls in line with the latest efforts by the FDA to promote and improve safety and effectiveness in an efficient manner. The current 510(k) framework, which has been in existence since the 1976 Medical Device Amendments will undergo some much-needed updates in the near future to adapt to the ever-evolving medical device landscape. The FDA has already taken steps this past year to begin the transformation process, including the release of a draft guidance regarding the abbreviated 510(k) program. Additionally, the agency recently shared a “performance report” describing various measures implemented in the last 10 years to improve the 510(k) pathway, with a spotlight on recent efforts. These actions taken by the FDA include:

Topics: 510(k) Program, FDA

Posted by Shawn Kennedy on Thu, Nov 12, 2015

What is the FDA Form 3674?

Recently, while on a monitoring visit for a physician sponsored IDE study in which IMARC was concurrently conducting a clinical audit, I was caught off guard by the question “do you know what the FDA Form 3674 is?”  I thought I had spent a good deal of my professional career working in the clinical research industry, I try my best to be a diligent student of the regulations and GCP guidelines, and even have tested my wits by passing the SOCRA certified clinical research professional exam.  However, I was stumped when it came to this mysterious form, albeit somewhat relieved that my co-monitor and the auditor that asked me were equally baffled by what it was.  At our auditor’s good suggestion, we took to finding the answer.  That night, she emailed FDAs FDAs [email protected] for their input.  This is really a fantastic tool in and of itself if you have not utilized it, someone from FDA will respond to your questions regarding good clinical practice in the field of clinical research.

Topics: 510(k) Program, Clinical Auditing, FDA, Form 3674

Posted by John Lehmann on Tue, Sep 01, 2015

Conducting a Well-Controlled Clinical Study When Clinical Data is Required

There continues to be much discussion over the FDA’s 510(k) program, which has led to controversy and confusion over the direction of the program. In fact, we have posted many blogs devoted to this topic, so we thought it was time to create a whitepaper focusing on the topic.

Topics: 510(k) Program, IMARC Whitepaper, FDA

Posted by John Lehmann on Wed, Mar 04, 2015

Conducting a Well-Controlled Clinical Study When Clinical Data is Required

There continues to be much discussion over the FDA’s 510(k) program, which has led to controversy and confusion over the direction of the program.  In fact, we have posted many blogs devoted to this topic, so we thought it was time to create a whitepaper focusing on the topic.

Topics: Whitepaper, 510(k) Program, IMARC Research, FDA